Wall Street analysts expect that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will report earnings per share of ($1.33) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Aerie Pharmaceuticals’ earnings. The highest EPS estimate is ($0.81) and the lowest is ($1.64). Aerie Pharmaceuticals posted earnings of ($0.71) per share in the same quarter last year, which suggests a negative year over year growth rate of 87.3%. The business is expected to issue its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($4.14) per share for the current financial year, with EPS estimates ranging from ($4.50) to ($3.35). For the next financial year, analysts forecast that the business will post earnings of ($1.72) per share, with EPS estimates ranging from ($2.35) to ($1.36). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.16). The business had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $1.16 million.
A number of analysts have commented on AERI shares. BidaskClub cut shares of Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 7th. Cowen increased their price target on shares of Aerie Pharmaceuticals from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. ValuEngine upgraded shares of Aerie Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 28th. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, Stifel Nicolaus increased their price target on shares of Aerie Pharmaceuticals from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Tuesday, September 11th. One research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $82.09.
In other news, COO Thomas A. Mitro sold 190,000 shares of the firm’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $60.27, for a total transaction of $11,451,300.00. Following the completion of the sale, the chief operating officer now owns 234,147 shares in the company, valued at approximately $14,112,039.69. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Casey C. Kopczynski sold 11,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $60.56, for a total transaction of $666,160.00. Following the sale, the insider now owns 138,187 shares of the company’s stock, valued at approximately $8,368,604.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 324,117 shares of company stock valued at $19,617,956. 10.53% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Summit Trail Advisors LLC raised its stake in Aerie Pharmaceuticals by 4,034.9% in the 1st quarter. Summit Trail Advisors LLC now owns 439,911 shares of the company’s stock worth $440,000 after purchasing an additional 429,272 shares in the last quarter. Frontier Capital Management Co. LLC acquired a new stake in Aerie Pharmaceuticals in the 2nd quarter worth about $24,685,000. BlackRock Inc. raised its stake in Aerie Pharmaceuticals by 9.0% in the 2nd quarter. BlackRock Inc. now owns 2,991,101 shares of the company’s stock worth $202,049,000 after purchasing an additional 246,686 shares in the last quarter. PointState Capital LP raised its stake in Aerie Pharmaceuticals by 524.7% in the 2nd quarter. PointState Capital LP now owns 281,600 shares of the company’s stock worth $19,022,000 after purchasing an additional 236,524 shares in the last quarter. Finally, FMR LLC raised its stake in Aerie Pharmaceuticals by 25.4% in the 2nd quarter. FMR LLC now owns 1,095,652 shares of the company’s stock worth $74,011,000 after purchasing an additional 221,582 shares in the last quarter. Institutional investors own 95.99% of the company’s stock.
AERI stock traded up $2.81 during trading hours on Monday, reaching $55.37. The stock had a trading volume of 537,487 shares, compared to its average volume of 383,652. The stock has a market cap of $2.78 billion, a P/E ratio of -16.43 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a current ratio of 10.27 and a quick ratio of 10.07. Aerie Pharmaceuticals has a fifty-two week low of $47.06 and a fifty-two week high of $74.75.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Recommended Story: What Factors Can Affect Return on Equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.